Intellipharmaceutics International Inc. (IPCI)

[fred198484]

OK - so Rexista is not dead and the stock therefore has something other than generics to look forward to over the next 18 months or so. That is definitely good, since if the FDA just deep-sixed Rexista today, we would only have the generics for a very long time and the stock's price-earnings ratio would never be high based on just those earnings.

What we don't know, however, remains significant:

1.) Exactly how many studies need to be done and how long will they take?
2.) What will those studies cost?
3.) How quickly will the FDA respond once the studies are completed?
4.) Where is the money for the studies coming from?
5.) Will IPCI raise just enough money to get by or will they raise much more than the minimum? Odidi now knows that his scraping for cash to get by approach of the past cost him valuable time with Rexista, Regbatin and PODRAS. He could well allow the new CFO to go out and raise a lot of money in order to avoid the mistakes of the past, even if it hurts his own position in the stock, not to mention ours.

So, it will be nice to see how the new and improved communications under the new CFO work out in the next couple of weeks and how clear an answer we get to the above questions.